• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ZLD
Click for more information
0.00% 65.0¢

ZELIRA THERAPEUTICS LIMITED - Announcements

Market Cap $7.716M  ! watchlist Created with Sketch. Add to my watchlist

Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company... Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
ZLD Clinical Trials to Commence in ChilePRICE SENSITIVE23/03/17
ZLD New Licence AgreementPRICE SENSITIVE21/03/17
ZLD Closure of Unmarketable Parcel Share Sale Facility14/03/17
ZLD Appendix 4D & FY17 Interim Financial ReportPRICE SENSITIVE27/02/17
ZLD Zelda Therapeutics to present activities update21/02/17
ZLD Investor Presentation08/02/17
ZLD Issue of Options under ESOP & Appendix 3B06/02/17
ZLD Quarterly Report and Appendix 4CPRICE SENSITIVE31/01/17
ZLD Unmarketable Parcel Share Sale Facility19/01/17
ZLD Appendix 3B11/01/17
ZLD Release from escrow11/01/17
ZLD Details of Company Address11/01/17
ZLD Shareholder Update09/01/17
ZLD Zelda to Test Formulations Against Pancreatic CancerPRICE SENSITIVE20/12/16
ZLD Company Secretary Appointment16/12/16
ZLD Sleep Disorder Clinical Trials UpdatePRICE SENSITIVE12/12/16
ZLD Collaboration Agreement with Telethon Kids InstitutePRICE SENSITIVE05/12/16
ZLD Significant Anti-Cancer Effect Observed in StudiesPRICE SENSITIVE30/11/16
ZLD Results of Meeting28/11/16
ZLD Becoming a substantial holder25/11/16
ZLD Change in substantial holding25/11/16
ZLD Change in substantial holding25/11/16
ZLD Zelda expands its Intellectual Property portfolioPRICE SENSITIVE25/11/16
ZLD Becoming a substantial holder23/11/16
ZLD OpenBriefing Recording with Dr Stewart WasherPRICE SENSITIVE23/11/16
ZLD Investor Presentation22/11/16
ZLD Zelda Therapeutics Debuts on ASX22/11/16
ZLD Zelda Therapeutics Pty Ltd - 30 June 2016 Accounts18/11/16
ZLD Zelda Therapeutics Pty Ltd - 31 December 2015 Accounts18/11/16
ZLD Updated Pro-Forma Statement18/11/16
ZLD Updated Statement of Commitments18/11/16
ZLD Confirmations18/11/16
ZLD Securities trading policy18/11/16
ZLD Top 20 holders18/11/16
ZLD Capital Structure and Restricted Securities18/11/16
ZLD Constitution18/11/16
ZLD Distribution schedule18/11/16
ZLD Appendix 1A and Information Form and Checklist18/11/16
ZLD Pre-reinstatement disclosure18/11/16
ZLD Reinstatement to Official Quotation - 22 November 2016PRICE SENSITIVE18/11/16
ZLD ASX Notice - Reinstatement to Official Quotation18/11/16
ZLD Initial Director's Interest Notice x 417/11/16
ZLD Final Director's Interest Notice x 317/11/16
ZLD Appendix 3B17/11/16
ZLD Successful $4m Capital Raising15/11/16
ZLD Supplementary Prospectus08/11/16
ZLD Quarterly Activities Report-ZLD.AX 31/10/16
ZLD Quarterly Cashflow Report-ZLD.AX 31/10/16
ZLD Notice of Annual General Meeting/Proxy Form-ZLD.AX 28/10/16
ZLD ASX Waiver Granted-ZLD.AX 26/10/16
ZLD Consolidation Complete-ZLD.AX 12/10/16
ZLD Supplementary Prospectus-ZLD.AX 12/10/16
ZLD Appendix 4G-GLN.AX 26/09/16
ZLD Annual Report-GLN.AX 23/09/16
ZLD Successful $4m Capital Raising Closes Over-Subscribed-GLN.AX 20/09/16
ZLD Letter to Shareholders-GLN.AX 04/08/16
ZLD Quarterly Activities Report-GLN.AX 29/07/16
ZLD Quarterly Cashflow Report-GLN.AX 29/07/16
ZLD Results of Meeting-GLN.AX 25/07/16
ZLD Suspension from Official Quotation-GLN.AX PRICE SENSITIVE25/07/16
ZLD Prospectus-GLN.AX PRICE SENSITIVE12/07/16
ZLD Securities Trading Policy-GLN.AX 11/07/16
ZLD Becoming a substantial holder-GLN.AX 08/07/16
ZLD Cancel - Consolidation/Split - GLN-GLN.AX 30/06/16
ZLD Consolidation/Split - GLN-GLN.AX PRICE SENSITIVE28/06/16
ZLD Notice of General Meeting-GLN.AX 21/06/16
ZLD Change in substantial holding-GLN.AX 14/06/16
ZLD Successful Completion of Pre-IPO Capital Raise-GLN.AX PRICE SENSITIVE30/05/16
ZLD Change of Registered Office-GLN.AX 09/05/16
ZLD Zelda Therapeutics Presentation-GLN.AX 02/05/16
ZLD Quarterly Activities Report-GLN.AX PRICE SENSITIVE29/04/16
ZLD Quarterly Cashflow Report-GLN.AX PRICE SENSITIVE29/04/16
ZLD Half Yearly Report and Accounts15/03/16
ZLD Leading Paediatric Oncologist Joins Scientific Advisor Board02/03/16
ZLD Distinguished Clinician Joins Zelda Scientific Advisor Board09/02/16
ZLD Quarterly Cashflow ReportPRICE SENSITIVE29/01/16
ZLD Quarterly Activities ReportPRICE SENSITIVE29/01/16
ZLD Zelda Therapeutics Presentation17/12/15
ZLD Gleneagle to Acquire Zelda Therapeutics Pty LtdPRICE SENSITIVE09/12/15
ZLD Trading HaltPRICE SENSITIVE07/12/15
ZLD Results of Meeting25/11/15
ZLD Quarterly Cashflow ReportPRICE SENSITIVE29/10/15
ZLD Quarterly Activities ReportPRICE SENSITIVE29/10/15
ZLD Appendix 3B and Section 708A(5) Notice23/10/15
ZLD Notice of Annual General Meeting/Proxy Form23/10/15
ZLD Capital RaisingPRICE SENSITIVE13/10/15
ZLD Appendix 4G22/09/15
ZLD Annual Report22/09/15
ZLD Myostin Merger not ProceedingPRICE SENSITIVE01/09/15
ZLD Quarterly Cashflow ReportPRICE SENSITIVE31/07/15
ZLD Quarterly Activities ReportPRICE SENSITIVE31/07/15
ZLD Change of Director's Interest Notice x 306/07/15
ZLD Appendix 3B30/06/15
ZLD Change of Share Registry Address12/06/15
ZLD Option Expiry Notice28/05/15
ZLD Quarterly Activities ReportPRICE SENSITIVE29/04/15
ZLD Quarterly Cashflow ReportPRICE SENSITIVE29/04/15
ZLD Half Yearly Report and Accounts16/03/15
ZLD Gleneagle to Merge with MyostinTherapeutics Pty LtdPRICE SENSITIVE16/03/15
ZLD Trading HaltPRICE SENSITIVE11/03/15
ZLD Clinical Trials to Commence in Chile
23/03/17PRICE SENSITIVE
ZLD New Licence Agreement
21/03/17PRICE SENSITIVE
ZLD Closure of Unmarketable Parcel Share Sale Facility
14/03/17
ZLD Appendix 4D & FY17 Interim Financial Report
27/02/17PRICE SENSITIVE
ZLD Zelda Therapeutics to present activities update
21/02/17
ZLD Investor Presentation
08/02/17
ZLD Issue of Options under ESOP & Appendix 3B
06/02/17
ZLD Quarterly Report and Appendix 4C
31/01/17PRICE SENSITIVE
ZLD Unmarketable Parcel Share Sale Facility
19/01/17
ZLD Appendix 3B
11/01/17
ZLD Release from escrow
11/01/17
ZLD Details of Company Address
11/01/17
ZLD Shareholder Update
09/01/17
ZLD Zelda to Test Formulations Against Pancreatic Cancer
20/12/16PRICE SENSITIVE
ZLD Company Secretary Appointment
16/12/16
ZLD Sleep Disorder Clinical Trials Update
12/12/16PRICE SENSITIVE
ZLD Collaboration Agreement with Telethon Kids Institute
05/12/16PRICE SENSITIVE
ZLD Significant Anti-Cancer Effect Observed in Studies
30/11/16PRICE SENSITIVE
ZLD Results of Meeting
28/11/16
ZLD Becoming a substantial holder
25/11/16
ZLD Change in substantial holding
25/11/16
ZLD Change in substantial holding
25/11/16
ZLD Zelda expands its Intellectual Property portfolio
25/11/16PRICE SENSITIVE
ZLD Becoming a substantial holder
23/11/16
ZLD OpenBriefing Recording with Dr Stewart Washer
23/11/16PRICE SENSITIVE
ZLD Investor Presentation
22/11/16
ZLD Zelda Therapeutics Debuts on ASX
22/11/16
ZLD Zelda Therapeutics Pty Ltd - 30 June 2016 Accounts
18/11/16
ZLD Zelda Therapeutics Pty Ltd - 31 December 2015 Accounts
18/11/16
ZLD Updated Pro-Forma Statement
18/11/16
ZLD Updated Statement of Commitments
18/11/16
ZLD Confirmations
18/11/16
ZLD Securities trading policy
18/11/16
ZLD Top 20 holders
18/11/16
ZLD Capital Structure and Restricted Securities
18/11/16
ZLD Constitution
18/11/16
ZLD Distribution schedule
18/11/16
ZLD Appendix 1A and Information Form and Checklist
18/11/16
ZLD Pre-reinstatement disclosure
18/11/16
ZLD Reinstatement to Official Quotation - 22 November 2016
18/11/16PRICE SENSITIVE
ZLD ASX Notice - Reinstatement to Official Quotation
18/11/16
ZLD Initial Director's Interest Notice x 4
17/11/16
ZLD Final Director's Interest Notice x 3
17/11/16
ZLD Appendix 3B
17/11/16
ZLD Successful $4m Capital Raising
15/11/16
ZLD Supplementary Prospectus
08/11/16
ZLD Quarterly Activities Report-ZLD.AX
31/10/16
ZLD Quarterly Cashflow Report-ZLD.AX
31/10/16
ZLD Notice of Annual General Meeting/Proxy Form-ZLD.AX
28/10/16
ZLD ASX Waiver Granted-ZLD.AX
26/10/16
ZLD Consolidation Complete-ZLD.AX
12/10/16
ZLD Supplementary Prospectus-ZLD.AX
12/10/16
ZLD Appendix 4G-GLN.AX
26/09/16
ZLD Annual Report-GLN.AX
23/09/16
ZLD Successful $4m Capital Raising Closes Over-Subscribed-GLN.AX
20/09/16
ZLD Letter to Shareholders-GLN.AX
04/08/16
ZLD Quarterly Activities Report-GLN.AX
29/07/16
ZLD Quarterly Cashflow Report-GLN.AX
29/07/16
ZLD Results of Meeting-GLN.AX
25/07/16
ZLD Suspension from Official Quotation-GLN.AX
25/07/16PRICE SENSITIVE
ZLD Prospectus-GLN.AX
12/07/16PRICE SENSITIVE
ZLD Securities Trading Policy-GLN.AX
11/07/16
ZLD Becoming a substantial holder-GLN.AX
08/07/16
ZLD Cancel - Consolidation/Split - GLN-GLN.AX
30/06/16
ZLD Consolidation/Split - GLN-GLN.AX
28/06/16PRICE SENSITIVE
ZLD Notice of General Meeting-GLN.AX
21/06/16
ZLD Change in substantial holding-GLN.AX
14/06/16
ZLD Successful Completion of Pre-IPO Capital Raise-GLN.AX
30/05/16PRICE SENSITIVE
ZLD Change of Registered Office-GLN.AX
09/05/16
ZLD Zelda Therapeutics Presentation-GLN.AX
02/05/16
ZLD Quarterly Activities Report-GLN.AX
29/04/16PRICE SENSITIVE
ZLD Quarterly Cashflow Report-GLN.AX
29/04/16PRICE SENSITIVE
ZLD Half Yearly Report and Accounts
15/03/16
ZLD Leading Paediatric Oncologist Joins Scientific Advisor Board
02/03/16
ZLD Distinguished Clinician Joins Zelda Scientific Advisor Board
09/02/16
ZLD Quarterly Cashflow Report
29/01/16PRICE SENSITIVE
ZLD Quarterly Activities Report
29/01/16PRICE SENSITIVE
ZLD Zelda Therapeutics Presentation
17/12/15
ZLD Gleneagle to Acquire Zelda Therapeutics Pty Ltd
09/12/15PRICE SENSITIVE
ZLD Trading Halt
07/12/15PRICE SENSITIVE
ZLD Results of Meeting
25/11/15
ZLD Quarterly Cashflow Report
29/10/15PRICE SENSITIVE
ZLD Quarterly Activities Report
29/10/15PRICE SENSITIVE
ZLD Appendix 3B and Section 708A(5) Notice
23/10/15
ZLD Notice of Annual General Meeting/Proxy Form
23/10/15
ZLD Capital Raising
13/10/15PRICE SENSITIVE
ZLD Appendix 4G
22/09/15
ZLD Annual Report
22/09/15
ZLD Myostin Merger not Proceeding
01/09/15PRICE SENSITIVE
ZLD Quarterly Cashflow Report
31/07/15PRICE SENSITIVE
ZLD Quarterly Activities Report
31/07/15PRICE SENSITIVE
ZLD Change of Director's Interest Notice x 3
06/07/15
ZLD Appendix 3B
30/06/15
ZLD Change of Share Registry Address
12/06/15
ZLD Option Expiry Notice
28/05/15
ZLD Quarterly Activities Report
29/04/15PRICE SENSITIVE
ZLD Quarterly Cashflow Report
29/04/15PRICE SENSITIVE
ZLD Half Yearly Report and Accounts
16/03/15
ZLD Gleneagle to Merge with MyostinTherapeutics Pty Ltd
16/03/15PRICE SENSITIVE
ZLD Trading Halt
11/03/15PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
65.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $7.716M
Open High Low Value Volume
66.0¢ 66.0¢ 65.0¢ $11 16

Buyers (Bids)

No. Vol. Price($)
1 696 62.5¢
 

Sellers (Offers)

Price($) Vol. No.
66.0¢ 248 1
View Market Depth
Last trade - 11.25am 29/11/2024 (20 minute delay) ?
ZLD (ASX) Chart

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
Australian Rare Earths bullish on early-stage uranium potential at Overland, SA Australian Rare Earths has asserted it's set to launch follow up drilling after aircore results show potential uranium downhole at Overland.
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
Southern Cross Gold zooms in on 9 new high-grade zones above 20g/t at Golden Dyke Southern Cross Gold Ltd has found 5.5 metres at 25.4 g/t, with drilling highlighting the presence of multiple zones of mineralisation
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.